TheraRadar
← Back
Data updated: Jun 28, 2026

TELIGENT

Pharma

TELIGENT is a pharmaceutical company focused on Cardiovascular, Infectious Disease, Dermatology.

1983
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Jan 20, 2027 — Foundayo (orforglipron)

TELIGENT's Key Drugs

TELIGENT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

TELIGENT's Recent FDA Approvals

New NDA/BLA approvals for TELIGENT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

TELIGENT's Therapeutic Areas

TELIGENT's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
1 drugs
Infectious Disease 33%
1 drugs
Dermatology 33%
1 drugs

TELIGENT's Top Competitors

TELIGENT's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

TELIGENT Pipeline Snapshot

Active clinical trials for TELIGENT across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling